Barclays Maintains an 'Equalweight' on Eli Lilly (LLY); Review of Solanezumab Results

Barclays maintains an 'Equalweight' on Eli Lilly (NYSE: LLY) price target of $39.00.

Analyst, C. Anthony Butler, said, "LLY announced intriguing outcomes of the EXPEDITION 1 and 2 studies: pooled data across two studies showed a statistically significant slowing of cognitive decline in the mild to moderate Alzheimer's disease population, and subgroup analyses showed a difference in the mild but not in the moderate group. Each study individually did not reach primary endpoints, however."

"...Assuming a launch in 2015-2016 for both agents, we estimate a NPV/share value of $4 or ~9% of LLY's total portfolio value."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $43.86 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Truist Securities Assumes Corcept Therapeutics (CORT) at Buy
• Wolfe Research Starts First Tracks Biotherapeutics (TRAX) at Outperform
• HSBC Upgrades Blue Star Limited (BLSTR:IN) to Buy